Analysts’ Weekly Ratings Updates for Marker Therapeutics (MRKR)

Several analysts have recently updated their ratings and price targets for Marker Therapeutics (NASDAQ: MRKR):

• 12/16/2025 – Marker Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Marker Therapeutics is now covered by analysts at HC Wainwright. They set a “buy” rating and a $10.00 price target on the stock.
• 12/8/2025 – Marker Therapeutics had its “buy” rating reaffirmed by analysts at UBS Group AG.
• 12/8/2025 – Marker Therapeutics is now covered by analysts at HC Wainwright. They set a “buy” rating and a $10.00 price target on the stock.
• 11/30/2025 – Marker Therapeutics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 11/22/2025 – Marker Therapeutics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 11/18/2025 – Marker Therapeutics was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.